This newsletter presents you the following key sessions:
1. Podcast with prof. Thomas Powles about the EV 301 trial: Phase III study of enfortumab vedotin versus
chemotherapy in pre-treated locally advanced or metastatic urothelial carcinoma
2. Combination therapy with pembrolizumab, docetaxel and prednisone for previously treated metastatic,
castration-resistant prostate cancer
3. Gemcitabine, split-dose cisplatin and pembrolizumab as neoadjuvant therapy before a radical
cystectomy in muscle-invasive bladder cancer patients
4. Adding apalutamide to abiraterone acetate significantly delays the time to radiographic progression in
patients with chemotherapy-naïve metastatic castration-resistant prostate cancer
5. Stereotactic ablative body radiotherapy in combination with pembrolizumab shows efficacy in first-line
for oligometastatic clear cell renal cell carcinoma
